In addition, acquired transferable LZD resistance genes have been reported, namely the cfr, cfr(B), cfr(C), optrA, and poxtA genes (Sadowy, 2018) . The cfr gene encodes a methylase modifying the C-8 position of A2503 residue in the 23S rRNA methylases (Kehrenberg et al., 2005; Schwarz et al., 2000) , and confers resistance not only to LZD but also to phenicols, lincosamides, pleuromutilins, and streptogramins (so called PhLOPS A resistance phenotype), but noticeably spares the novel oxazolidinone tedizolid (Long et al., 2006) . This gene has been identified in S. aureus, enterococci, Streptococcus suis, and Bacillus spp., but also in several Gram-negative bacteria such as Escherichia coli and Proteus vulgaris. The cfr(B) gene sharing 72% nucleotide identity with cfr was found in S. aureus, also conferring a PhLOPS A resistance phenotype (Marín et al., 2015) . The cfr(C) gene encoding a protein sharing ca. 55% amino acid identity with Cfr(A) and Cfr(B) was found in Campylobacter spp. (Tang et al., 2017) .
In addition to those Cfr-like 23S rRNA methylases, another acquired resistance trait to LZD has been reported, being OptrA (Wang et al., 2015) . It belongs to the ABC-F family of ATP-binding proteins, and has been characterized as a ribosomal protection protein. The corresponding gene was first identified in E. faecalis, and later in Staphylococcus sciuri and Streptococcus gallotycus (Sharkey et al., 2016) .
Finally, another ribosomal protection protein, PoxtA, was recently identified from a human methicillin-resistant S. aureus (MRSA) clinical isolate isolate, and further identified in E. faecalis and E. faecium of animal origin (Antonelli et al., 2018) . That resistance mechanism confers reduced susceptibility not only to oxazolidinone, but also to tetracyclines and phenicols.
Taking in account the potential clinical threat represented by a diffusion of LZD-resistant strains, our aim was to develop a selective culture medium for screening of LZD-resistant bacteria both among human and animal isolates.
Material and methods

Preparation of the SuperLinezolid medium
The necessity to prevent contamination by Gram negatives and fungi was taken in account for the development of this medium. Based on our own experience of developing screening media (Nordmann et al., 2012 (Nordmann et al., , 2016 , the optimal medium retained was based on the Brain Heart Infusion (BHI) medium (ref 3,564,014; Bio-Rad, Cressier, Switzerland). This medium was rich enough to enhance the growth of the Gram-positive isolates we tested.
To determine the optimal concentrations of each compound of the SuperLinezolid medium, a series of different preliminary tests was performed, using six linezolid-resistant and two linezolid-susceptible isolates, including Staphylococci and Enterococci strains. Using an inoculum with an optical density of 0.5 Mac Farland (inoculum of~10 8 CFU/ ml), a 1000-fold dilution of the strains to be tested was made in normal saline solution and a 100-μl volume was plated onto the SuperLinezolid medium. To quantify the viable bacteria in each dilution, BHI agar medium was inoculated concomitantly with 100 μl of suspension and incubated overnight at 37°C. A range of concentrations varying from 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, and 4 mg/L was tested, and the 1.5 mg/L concentration was retained since it allowed to obtain the optimal sensitivity and specificity values. Colistin sulfate (tablets, MAST DIAGNOSTICS, Merseyside, UK) was added in the medium at a final concentration of 15 μg/ml to prevent the growth of colistin-susceptible Gram-negative isolates. In addition, considering that growth of colistin-resistant Gram-negative strains might be a source of contamination (particularly with species being intrinsically resistant or heteroresistant to colistin such as Proteus spp., Serratia spp., Hafnia spp., or Enterobacter cloacae) (Poirel et al., 2017) , aztreonam was added at a concentration of 2 μg/ml. While addition of aztreonam contributed to inhibit growth of Gramnegative bacteria (unless they produced broad-spectrum ß-lactamases), it did not modify the growth of the Gram-positive bacteria tested, including LZD-susceptible and -resistant isolates. Amphotericin B (Bristol-Myers-Squibb, Rueil-Malmaison, France) was added as an antifungi molecule at a final concentration of 5 μg/ml. Cultures were incubated at 37°C during 18 h. When no growth was observed after 24 h, the incubation period was extended to 48 h to definitely assess that no growth actually occurred.
The instructions for the preparation of SuperLinezolid medium are indicated in Table 1 . The stock solutions may be kept at −20°C. For preparing the SuperLinezolid medium, the diluted powder of BHI was autoclaved at 121°C for 15 min. After cooling this medium for one hour at 56°C, the antibiotic stock solutions were added (Table 1) . Once poured, the plates were stored at 4°C and protected from direct light exposure. The SuperLinezolid plates were kept one month and no major effect on its performances was noticed over time (data not shown). (See Fig. 1.) A total of thirty-seven isolates of various Gram-positive species (Enteroccocus faecium, Enterococcus faecalis, Enterococcus casseliflavus, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus capitis) recovered in France were tested to evaluate the performance of the SuperLinezolid medium. Seventeen of those isolates were resistant to LZD, and twenty isolates were susceptible. In addition, a total of eleven Gram-negative isolates were tested, including Enterobacteriaceae (n = 9), Pseudomonas aeruginosa (n = 1), and Acinetobacter baumannii (n = 1) isolates. All those isolates were clonally-unrelated (data not shown).
The lowest limit of detection with the SuperLinezolid medium was determined for all the tested strains. Using an inoculum with an optical density of 0.5 McFarland standard (inoculum of ∼10 8 CFU/ml), serial 10-fold dilutions of the isolates were made in normal saline, and 100-μl portions were plated onto the SuperLinezolid medium. To quantify the viable bacteria in each dilution, BHI agar was inoculated concomitantly with 100 μl of suspension and was incubated overnight at 37°C. The number of viable colonies was counted after 24 h of culture at 37°C. The sensitivity and specificity cut-off values were set at 1 × 10 3 CFU/ml i.e., a limit value of 1 × 10 3 CFU/ml and above was considered as « not efficiently detected » (Schwarz et al., 2000) . Spiked stools were also tested using this selective culture medium, done in triplicate. Spiked fecal samples were made by adding 100 μl of each strain dilution to 900 μl of fecal suspension that was obtained by suspending 5 g of freshly pooled feces from three healthy volunteers in 50 ml of distilled water, as done previously (Nordmann et al., 2016) . A non-spiked fecal suspension was used as negative control. The lowest detection limit was determined by plating 100 μl of each dilution on the screening medium. The sensitivity and specificity were determined using the same cut-off value set at ≥10 3 CFU/mL (Nordmann et al., 2016) .
MICs of LZD were determined using the broth microdilution method in Mueller-Hinton broth, as recommended by the CLSI (Clinical and Laboratory Standards Institute, 2018). For each strain, an inoculum corresponding to 5 × 10 5 CFU/ml was distributed in the 96-well tray (Sarstedt, Nümbrecht, Germany) . The evaluation of the selective medium was performed in triplicate.
According to the CLSI and EUCAST breakpoints (www.eucast.org/ clinical_breakpoints/), Staphylococcus spp. and Enterococcus spp. isolates with MIC values of LZD ≤ 4 mg/L are categorized as susceptible, whereas those with MIC values ≥8 mg/L are categorized as resistant.
Results
Overall, all LZD-resistant Gram-positive isolates tested grew on the SuperLinezolid medium after 24 h, except three LZD-resistant S. epidermidis isolates (HM-1, HM-2, and HM-6) that did not grow after 24 h of incubation (even at a concentration of 10 3 CFU/ml), but grew after 48 h ( Table 2) . As expected, no growth was observed for the 11 Gram-negative isolates tested.
The sensitivity was found to be 82% at 24 h (3 out of 17 isolates being missed), and reached 100% at 48 h. At 48 h, a single LZD-susceptible isolate grew (specificity 95%).
For all the LZD-susceptible isolates, the lowest limit of detection was found above the cut-off value of 10 3 CFU/ml, being in fact ≥1 × 10 6 CFU/ ml (Table 2) . By contrast, all the LZD-resistant isolates grew on the SuperLinezolid medium in 24 h and the lowest limit of detection was below the cut-off value. All LZD-susceptible Gram-positive did not growth after 24 h of incubation when the inoculum was up to 10 3 CFU/ml; small colonies were obtained only for a single isolate (S. aureus 2973) after 48 h of incubation when using this same inoculum. Therefore, a specificity of 100% was observed after a 24-h culture. Finally, no Gram-negative isolate grew after either 24 h or 48 h of incubation.
The spiked stools containing LZD-resistant strains grew with a lowest detection limit ranging from 10 1 to 10 2 CFU/ml (Table 3) , thus nicely corresponding to the required sensitivity. In addition, no false-positive isolate was recovered, thus showing an excellent specificity.
Discussion
We developed here a selective medium allowing screening and detection of Gram-positive bacteria exhibiting resistance to LZD. Considering that LZD-resistant isolates are currently emerging in different parts of the world, this selective medium may be used to perform prospective screening, and epidemiological surveys. Some surveys had used media supplemented with LZD for selection of LZD-resistant isolates but neither systematic evaluation nor development of such media had been performed (Bourgeois-Nicolaos et al., 2014; Lode et al., 2001) .
The SuperLinezolid medium may detect all clinically-relevant bacterial species exhibiting resistance to LZD, regardless of the resistance mechanism, and regardless of their resistance level to LZD. Growth of most isolates showing MICs of LZD ranging from 8 to N256 μg/ml on this selective medium was confirmed. These resistant isolates were either S. aureus, S. epidermidis, E. faecium, or S. capitis. Failure to detect any LZDresistant isolate tested was observed in three cases after a 24-h culture, corresponding to S. epidermidis isolates having an MIC at 8 or 16 μg/ml, therefore close to the breakpoint. The sensitivity was improved and all isolates detected at 48 h; however, the specificity at 48 h was lower, with 6 out of 20 LZD-susceptible isolates being recovered. It seems therefore that a 24-h growth is recommended. An extended evaluation of this selective medium is needed to guarantee high specificity and high sensitivity of the selection. We may admit that our study was performed with a limited number of isolates (due to limited isolates available in our collection), nevertheless we believe that the performances of the SuperLinezolid medium as obtained here do have a significant value. This medium offers the possibility either to assess the LZD resistance feature by selecting such isolates after re-striking of mixed cultures, but most of all to select for those LZD-resistant isolates from stools in a context of direct screening.
Therefore, the use of this selective medium may contribute to rapidly identify carriers of LZD-resistant isolates, and consequently to rapidly implement infection control measures in order to limit their spread in hospital settings.
Finally, this medium may be also useful for screening food-producing animal reservoirs. Indeed, resistance to LZD in Enterococci has been increasingly identified particularly in swine, poultry and cattle, mainly in China (Fang et al., 2018) . An animal reservoir of LZD-resistant strains has been demonstrated for a series of bacterial species, including E. faecalis and E. faecium (pigs and chicken), but also for Enterococcus gallinarum, Enterococcus casseliflavus, Enterococcus thailandicus, and Enterococcus suis (pigs) (Sadowy, 2018) . Prospective surveys may therefore be conducted by veterinary networks in order to evaluate the rate of LZDresistant Gram positives in animal husbandries, and identify possible reservoirs.
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